See "The Man Behind State's Most Successful Startup"
The main findings so far are dose-dependent weight loss in phase 2 studies, frequent gastrointestinal side effects, and ongoing questions about long-term safety, eligibility, and approval
This is a rough estimate and should be validated with your prescribing provider
Looking at the data across all four compounds, I keep coming back to one point: Retatrutides male results alone exceed the best results from Semaglutide for either gender
Neither intracellular GSH nor GSH:GSSG differed between M/M and SA
Instead, they might work best alongside other therapies, like cognitive behavioral therapy (CBT), offering a more complete approach to mental well-being, much like how antidepressants are often combined with therapy [9330]